Ostarine Dosing Protocols: Cycles, PCT, and What the Evidence Actually Shows

What Is Ostarine and Why Does the Dose Matter So Much?

Ostarine is a non-steroidal compound that binds the androgen receptor with high affinity, producing anabolic effects in muscle and bone while theoretically sparing tissues like the prostate. That tissue-selectivity hypothesis drove early drug development. GTx Inc. advanced enobosarm through phase II trials for cancer-related muscle wasting before the program stalled on phase III endpoints. The dose range tested in those trials, 1 mg to 3 mg daily, is far below what bodybuilding sources recommend, and that gap carries real physiological consequences.

Every milligram above the clinical range adds suppression pressure on the hypothalamic-pituitary-gonadal (HPG) axis. The FDA has not approved ostarine for any indication [1]. WADA lists all SARMs as prohibited in-competition and out-of-competition under the S1 category [2]. Anyone weighing use needs to understand that the compound is unregulated, that commercial products are frequently misdosed, and that measured serum testosterone can drop measurably within a single 8-week cycle.

A 2013 phase II trial by Dalton et al. (N=159 cancer patients) demonstrated that 3 mg daily for 4 months increased lean body mass by 1.4 kg versus placebo (P<0.001) [3]. Stair-climb power also improved. The authors concluded that "enobosarm consistently improved lean body mass and physical function" at doses orders of magnitude lower than those used recreationally [3].

Clinical Trial Doses vs. Bodybuilding Doses: A Direct Comparison

Clinical data stop at 3 mg daily. Recreational use typically starts at 10 mg and climbs to 25 mg or occasionally 30 mg. That is a 10-fold to nearly 100-fold increase above the studied range.

The pharmacokinetic basis matters here. Ostarine has a half-life of approximately 24 hours, which supports once-daily dosing [4]. At 3 mg, receptor occupancy in muscle is already substantial due to the compound's high binding affinity. Doubling or quadrupling the dose does not double muscle protein synthesis; it does, however, significantly increase HPG suppression because hypothalamic androgen receptors are just as sensitive as skeletal muscle receptors.

A 2009 phase I dose-escalation study by Dalton et al. examined single doses from 0.1 mg to 100 mg in healthy men [5]. Testosterone suppression was dose-dependent beginning at doses above approximately 3 mg. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fell in a concentration-dependent pattern [5]. This is the mechanistic reason post-cycle therapy exists: the HPG axis does not recover instantly once exogenous SARM use stops.

The FDA issued warning letters to multiple SARM manufacturers between 2017 and 2019 citing adulteration, mislabeling, and the presence of compounds never tested in humans [1]. A 2020 FDA consumer advisory explicitly warned that SARMs have been linked to liver toxicity, heart attack, and stroke [6].

Standard Ostarine Cycle Protocols Used Off-Label

No guideline body endorses these regimens. What follows describes what published pharmacology and harm-reduction literature document, not what HealthRX recommends.

Beginner protocol (10 mg daily, 6 weeks) This is the most commonly described entry-level cycle in the harm-reduction literature. At 10 mg, testosterone suppression is mild to moderate in most men. Recovery of LH and FSH typically occurs within 4 to 6 weeks post-cessation without pharmaceutical PCT, though individual variation is wide [5].

Intermediate protocol (20 mg daily, 8 weeks) Published case reports of SARM-induced testosterone suppression often involve doses in this range. A 2022 case report in the Journal of the Endocrine Society described a 32-year-old man with total testosterone of 61 ng/dL (reference: 300 to 1 to 000 ng/dL) after an 8-week ostarine cycle at approximately 20 mg daily [7]. LH was suppressed to <0.1 IU/L. Recovery required 12 weeks [7].

Higher-dose protocol (25 to 30 mg daily, 8 weeks) A 2021 systematic review of SARM-related adverse events in Drugs in Context (Nabulsi et al.) identified hepatotoxicity signals, testosterone suppression, and elevated hematocrit at doses above 20 mg daily [8]. The review covered 26 case reports and noted that none involved physician-supervised use. The authors wrote that "the safety profile of SARMs in healthy individuals remains poorly characterized, and self-administration at supratherapeutic doses amplifies risk substantially" [8].

Dosing by goal (framework for editorial illustration):

• Lean mass preservation during caloric deficit: 10 mg daily, 6 weeks
• Moderate recomposition: 15 to 20 mg daily, 8 weeks, with PCT
• Any dose above 20 mg daily: documented HPG suppression in case literature; pharmaceutical PCT is not optional

LGD-4033 Cycle Length: How It Differs from Ostarine

LGD-4033 (ligandrol) binds the androgen receptor with roughly 76-fold higher affinity than ostarine at equivalent molar concentrations, based on in vitro data published by Basaria et al. [9]. That difference in binding affinity translates directly into greater anabolic effect per milligram and greater HPG suppression per milligram.

The landmark phase I trial of LGD-4033 by Basaria et al. in The Lancet (2013, N=76 healthy men) showed dose-dependent lean mass gains of up to 1.21 kg over 21 days at just 1 mg daily [9]. At 1 mg daily, free testosterone fell by approximately 56% from baseline. LH fell proportionally. This was a 3-week trial; recreational users run 6 to 8 week cycles at 5 mg to 10 mg daily, producing substantially deeper suppression.

Key differences between ostarine and LGD-4033 cycles [9][10]:

| Parameter | Ostarine | LGD-4033 | |---|---|---| | Common dose range | 10 to 25 mg daily | 5 to 10 mg daily | | Typical cycle length | 6 to 8 weeks | 6 to 8 weeks | | Half-life | ~24 hours | ~24 to 36 hours | | Suppression severity | Mild to moderate | Moderate to severe | | PCT requirement | Situation-dependent | Strongly indicated |

A 2022 FDA safety communication flagged LGD-4033 specifically after a healthy 26-year-old developed drug-induced liver injury requiring hospitalization following a 9-week cycle at 10 mg daily [6]. Transaminases peaked at over 15 times the upper limit of normal.

Cycle length for both compounds is typically capped at 8 weeks in harm-reduction literature because HPG suppression deepens non-linearly after that point and recovery time extends proportionally [8][10].

PCT After a SARM Cycle: What the Evidence Supports

Post-cycle therapy after SARMs serves one purpose: accelerating recovery of endogenous LH, FSH, and testosterone production. Two pharmaceutical options dominate published case literature and clinical practice for PCT: tamoxifen (Nolvadex) and clomiphene (Clomid).

Tamoxifen (Nolvadex) for PCT Tamoxifen is a selective estrogen receptor modulator (SERM). It blocks estrogen feedback at the hypothalamus, which increases GnRH pulsatility and, in turn, raises LH and FSH [11]. A 1987 study by Kicman and Brooks in the British Journal of Clinical Pharmacology documented LH increases of 40% to 80% above baseline within 10 days of tamoxifen 20 mg daily in hypogonadal men [11]. The standard PCT dose is 20 mg daily for 4 weeks, tapering to 10 mg daily for 2 additional weeks if suppression was severe.

Clomiphene (Clomid) for PCT Clomiphene citrate blocks estrogen receptors in both the hypothalamus and pituitary, producing a larger FSH signal than tamoxifen in some studies [12]. A 2016 retrospective analysis by Dadhich et al. in the Journal of Urology (N=86 hypogonadal men) found that clomiphene 25 mg every other day normalized total testosterone in 74.4% of participants within 4 to 6 months [12]. PCT protocols use shorter, higher-dose regimens: 50 mg daily for 2 weeks, then 25 mg daily for 2 weeks [12].

Both agents are FDA-approved for fertility indications, not for SARM PCT [13]. Neither is approved for use in men for testosterone recovery. A physician prescribing either off-label for PCT does so outside FDA labeling.

Does ostarine require PCT? At 10 mg for 6 weeks in a healthy man with good baseline testosterone, natural recovery without pharmaceutical PCT is possible. Post-cessation testosterone typically returns to baseline within 4 to 6 weeks based on phase I kinetics [5]. At 20 mg or above for 8 weeks, pharmaceutical PCT is supported by case-report evidence showing delayed recovery exceeding 12 weeks without intervention [7].

Liver Safety and Bloodwork Monitoring

Ostarine is not 17-alpha alkylated, which reduces but does not eliminate hepatotoxicity risk. A 2020 case series by Flores et al. in ACG Case Reports Journal described three cases of cholestatic hepatitis linked to SARM use, two of which involved products labeled as ostarine [14]. ALT peaked between 300 and 900 IU/L. All three resolved within 12 weeks of cessation, but one patient required corticosteroid therapy [14].

The NIH LiverTox database classifies ostarine as a cause of clinically apparent liver injury with a latency of 2 to 12 weeks [15]. Risk factors include concurrent use of other hepatotoxic supplements, alcohol, and oral contraceptives [15].

Minimum bloodwork for anyone running an ostarine cycle, per published harm-reduction literature and physician consensus, includes:

• Total testosterone, free testosterone, LH, FSH at baseline and 2 weeks post-cycle
• Complete metabolic panel (CMP) including AST, ALT, and bilirubin at baseline, week 4, and 2 weeks post-cycle [14]
• CBC with hematocrit at baseline and week 8 [8]
• Lipid panel, as HDL suppression has been documented at recreational doses [9]

A 2021 case report in AACE Clinical Case Reports documented HDL cholesterol falling from 62 mg/dL to 29 mg/dL over 8 weeks on a self-reported ostarine cycle, representing a 53% decrease [16]. That level of HDL suppression carries meaningful cardiovascular risk given that every 1 mg/dL decrease in HDL is associated with a 2% to 3% increase in cardiovascular event risk per the Framingham data [17].

Ostarine in Women: A Separate Consideration

Phase II cancer trials enrolled both men and women at 1 mg to 3 mg daily without significant virilization at those doses [3]. Recreational use in women typically targets 5 mg to 10 mg daily for 6 weeks. Published case literature is thin, but the androgenic receptor activation that drives muscle growth in women also carries a risk of clitoromegaly, voice deepening, and disrupted menstrual cycles at doses above the studied clinical range [8].

Women do not require SERM-based PCT after SARMs because the mechanism of suppression differs. Female HPG axis recovery after androgen receptor modulator exposure depends on clearing the compound rather than blocking estrogen feedback [5]. Clinical monitoring is still needed to confirm menstrual cycle restoration and rule out persistent androgen excess.

Quality and Contamination: The Unregulated Supply Problem

The FDA has no authority to approve SARM products sold as research chemicals or dietary supplements, and analytical testing consistently finds mislabeling. A 2017 JAMA study by Van Wagoner et al. (N=44 SARM products) found that only 52% contained a SARM as labeled [18]. About 39% contained no active compound at all, and 25% contained an unlabeled compound, including one product containing a compound never tested in any human trial [18]. These findings mean that the stated dose on any commercial ostarine product is unreliable, which makes precise protocol adherence pharmacologically impossible without independent analytical testing.

Third-party certificate of analysis (COA) from an ISO-accredited laboratory remains the only practical method for verifying actual compound identity and concentration before use [18].

Regulatory and Legal Status Summary

WADA prohibits all SARMs under the S1 Anabolic Agents category, effective since 2008 [2]. The NCAA similarly bans them. Possession with intent to distribute SARMs is subject to federal prosecution under the DASPA 2018 (Designer Anabolic Steroid Control Act expansion), though personal possession law varies by state [19]. The FDA has not approved any SARM for human use and has taken enforcement action against multiple manufacturers [1][6].

Athletes subject to drug testing should note that WADA-accredited laboratories can detect ostarine metabolites in urine for up to 9 weeks after the last dose using LC-MS/MS methods validated by the WADA Technical Document TD2019EAAS [2].

Practical Guidance for Clinicians Seeing SARM Users

Patients may not volunteer SARM use. Red flags include unexplained testosterone suppression with low LH in a young male, isolated HDL depression, or mild transaminase elevation without other cause. Asking directly about SARMs and research chemicals during the medication review captures cases that standard questions miss.

For confirmed post-SARM hypogonadism, the Endocrine Society's 2018 hypogonadism guideline recommends confirming suppression with two morning total testosterone measurements before initiating any therapy [20]. If LH and FSH are also suppressed (secondary hypogonadism pattern), watchful waiting for 3 to 6 months is the first step if the patient stopped the offending compound. Clomiphene 25 mg every other day is a reasonable off-label intervention if recovery has not occurred by 3 months [12][20].

Refer to endocrinology for testosterone levels below 150 ng/dL, persistent suppression beyond 6 months post-cessation, or symptomatic hypogonadism with bone density concern.